长期甲巯咪唑治疗可提高Graves病缓解率:一项随机临床试验
该随机平行组试验纳入302例初诊Graves甲亢患者,在甲巯咪唑治疗18-24个月后,将258例(85.4%)随机分为长期组(n=130,继续治疗36-102个月,总疗程60-120个月)和常规组(n=128,停药)。停药后随访48个月,长期组复发率15%(18/119),常规组53%(65/123)。结论:低剂量甲巯咪唑总疗程60-120个月安全有效,缓解率远高于常规18-24个月疗程。
要点
- 长期甲巯咪唑总疗程60-120个月可使Graves病停药后48个月复发率降至15%。
- 常规18-24个月疗程停药后48个月复发率为53%。
- 长期治疗未见新的甲巯咪唑相关不良反应。
核心结论
- 低剂量甲巯咪唑总疗程60-120个月可安全有效地治疗Graves甲亢,缓解率远高于常规18-24个月疗程。
研究设计与样本
- 随机平行组研究,纳入302例未治疗首次发作的Graves甲亢患者,甲巯咪唑治疗18-24个月后258例(85.4%)随机分组。
- 长期组n=130,继续治疗36-102个月(计划总疗程60-120个月);常规组n=128,停药。
- 停药后随访48个月,采用Cox比例风险模型分析常规疗程后复发相关因素。
主要发现
- 甲巯咪唑实际治疗时间:长期组95±22个月,常规组19±3个月。
- 停药后48个月内复发:长期组15%(18/119),常规组53%(65/123)。
- 常规组中,年龄较大、三碘甲状腺原氨酸或促甲状腺素受体抗体浓度较高、促甲状腺素浓度较低、携带rs1879877 CD28多态性或DQB1-05 HLA多态性与复发独立相关。
关键数值与推荐
- 长期组计划甲巯咪唑总疗程60-120个月,实际95±22个月;常规组实际19±3个月。
- 停药后随访48个月,长期组复发率15%(18/119),常规组53%(65/123)。
临床怎么用
- 对初诊Graves甲亢患者,在甲巯咪唑治疗18-24个月后继续低剂量长期治疗至总疗程60-120个月,可显著提高缓解率。
- 长期治疗期间未见新的不良反应,但仍需监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Studies differ regarding whether, compared with courses of conventional duration, longer-term antithyroid drug treatment increases frequency of remission in patients with Graves' hyperthyroidism. We prospectively conducted a randomized, parallel-group study comparing relapse rates in patients receiving longer-term versus conventional-length methimazole therapy. We also sought variables associated with relapse following the latter. Methods: We enrolled 302 consecutive patients with untreated first episodes of Graves' hyperthyroidism. After 18-24 months of methimazole, 258 patients (85.4%) were randomized to an additional 36-102-month courses ("long-term group": n = 130; scheduled total time on methimazole: 60-120 months) or discontinuation of methimazole ("conventional group": n = 128). Patients were followed 48 months postmethimazole cessation. We performed Cox proportional hazards modeling to identify factors associated with relapse after conventional courses. Results: Methimazole was given for 95 ± 22 months in long-term patients and 19 ± 3 months in the conventional group. Fourteen patients experienced cutaneous reactions and 2 liver enzyme elevations during the first 18 months of treatment; no further methimazole-related reactions were observed despite therapy for up to another 118 months. Hyperthyroidism recurred within 48 months postmethimazole withdrawal in 15% (18/119) of long-term patients versus 53% (65/123) of conventional group patients. In the conventional group, older age, higher triiodothyronine or thyrotropin receptor antibody concentrations, lower thyrotropin concentration, or possession of the rs1879877 CD28 polymorphism or the DQB1-05 HLA polymorphism were independently associated with relapse. Conclusion: Administration of low-dose methimazole for a total of 60-120 months safely and effectively treats Graves' hyperthyroidism, with much higher remission rates than those attained by using conventional 18-24-month courses.
引用
- Azizi F, Amouzegar A, Tohidi M, et al. Increased Remission Rates After Long-Term Methimazole Therapy in Patients with Graves' Disease: Results of a Randomized Clinical Trial. Thyroid. 2019. PMID: 31310160. doi:10.1089/thy.2019.0180
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。